Searched for: person:sulmae01
in-biosketch:true
Commentary: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines Update for the Role of Emerging Therapies in the Management of Patients With Metastatic Brain Tumors
Shi, Yuhao; Sulman, Erik P
PMID: 40183551
ISSN: 1524-4040
CID: 5819402
Outcomes of concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for melanoma brain metastases
Fu, Allen Ye; Bernstein, Kenneth; Zhang, Jeff; Silverman, Joshua; Mehnert, Janice; Sulman, Erik P; Oermann, Eric Karl; Kondziolka, Douglas
PURPOSE/OBJECTIVE:Immune checkpoint inhibition (ICI) has revolutionized the treatment of melanoma care. Stereotactic radiosurgery combined with ICI has shown promise to improve clinical outcomes in prior studies in patients who have metastatic melanoma with brain metastases. However, others have suggested that concurrent ICI with stereotactic radiosurgery can increase the risk of complications. METHODS:We present a retrospective, single-institution analysis of 98 patients with a median follow up of 17.1 months managed with immune checkpoint inhibition and stereotactic radiosurgery concurrently and non-concurrently. A total of 55 patients were included in the concurrent group and 43 patients in the non-concurrent treatment group. Cox proportional hazards models were used to assess the relation between concurrent or non-concurrent treatment and overall survival or local progression-free survival. The Wald test was used to assess significance. Significant differences between patients in both groups experiencing adverse events including adverse radiation effects, perilesional edema, and neurological deficits were tested for using the Chi-square or Fisher's exact test. RESULTS:Patients receiving concurrent versus non-concurrent ICI showed a significant increase in overall survival (median 37.1 months, 95% CI: 18.9 months - NA versus median 11.4 months, 95% CI: 6.4-33.2 months, p = 0.0056) but not local progression-free survival. There were no significant differences between groups with regards to adverse radiation effects (2% versus 3%), perilesional edema (20% versus 9%), neurological deficits (3% versus 20%). CONCLUSION/CONCLUSIONS:These results suggest that the timing of ICI does not increase risk of neurological complications when delivered within 4 weeks of SRS.
PMID: 40183901
ISSN: 1573-7373
CID: 5819412
Clinical and Genetic Markers of Vascular Toxicity in Glioblastoma Patients: Insights from NRG Oncology RTOG-0825
Strauss, Joshua D; Gilbert, Mark R; Mehta, Minesh; Li, Ang; Ms, Renke Zhou; Bondy, Melissa L; Sulman, Erik P; Yuan, Ying; Liu, Yanhong; Vera, Elizabeth; Wendland, Merideth M; Stieber, Volker W; Puduvalli, Vinaykumar K; Choi, Serah; Martinez, Nina L; Robins, H Ian; Hunter, Grant K; Lin, Chi-Fan; Guedes, Vivian A; Richard, Melissa A; Pugh, Stephanie L; Armstrong, Terri S; Scheurer, Michael E
BACKGROUND:Glioblastoma (GBM) is an aggressive form of brain cancer in which treatment is associated with toxicities that can result in therapy discontinuation or death. This analysis investigated clinical and genetic markers of vascular toxicities in GBM patients during active treatment. METHODS:591 Non-Hispanic White GBM patients with clinical data were included in the analysis from NRG RTOG-0825. Genome-wide association studies (GWAS) were performed from genotyped blood samples (N=367) by occurrence of thrombosis or hypertension (grade ≥2). A clinical prediction model was produced for each vascular toxicity. Significant GWAS variants were then added to the clinical model as a single nucleotide polymorphism (SNP) -dose effect variable to produce the final genetic models. RESULTS:Thrombosis and hypertension were experienced by 62 (11%) and 59 (10%) patients, respectively. Patients who experienced hypertension displayed improved survival over those without hypertension (median overall survival: 25.72 vs 15.47 months, p=0.002). The genetic model of thrombosis included corticosteroid use (OR: 7.13, p=0.02), absolute neutrophil count (OR: 1.008, p=0.19), body surface area (OR: 18.87, p=0.0008), and the SNP-dose effect (3 variants; OR: 3.79, p<.0001). The genetic model of hypertension included bevacizumab use (OR: 0.97, p=0.95) and the SNP-dose effect (6 variants; OR: 4.44, p<.0001). CONCLUSION/CONCLUSIONS:In this study, germline variants were superior in predicting hypertension than clinical variables alone. Additionally, corticosteroid use was a considerable risk factor for thrombosis. Future investigations should confirm the hazard of corticosteroid use on thrombosis and the impact of bevacizumab in other malignancies after accounting for the genetic risk of hypertension.
PMID: 39549280
ISSN: 1523-5866
CID: 5754042
Integral Dose or Mean Dose for Predicting Radiosurgery Response in Patients With Trigeminal Neuralgia: A Proposal to Target the Narrowest Part of the Nerve
Meng, Ying; Santhumayor, Brandon; Mashiach, Elad; Bernstein, Kenneth; Gurewitz, Jason; Cooper, Benjamin T; Sulman, Erik; Silverman, Joshua; Kondziolka, Douglas
BACKGROUND AND OBJECTIVES/OBJECTIVE:Stereotactic radiosurgery (SRS) is effective for patients with medically refractory trigeminal neuralgia with a 75%-90% response rate. Consideration of the integral dose (ID) to the target nerve within the 50% isodose line was reported to help select prescription doses to maximize effectiveness and minimize bothersome numbness. The objective of this study was to externally validate the ID as a predictor of outcomes after SRS. METHODS:We reviewed the outcomes and parameters of 94 consecutive patients of type 1 trigeminal neuralgia who had SRS for the first time where nerve ID was calculated. 70% of the prescription doses were 80 Gy, with 28% at 85 Gy, and 2% at 70 Gy. RESULTS:The median follow-up time was 14.4 months. A total of 85 (90%) patients reported significant pain relief (Barrow Neurological Institute I-III) after initial SRS. The median pain recurrence-free survival was 82 months (95% CI 41.1-NA), and estimates at 1, 3, and 5 years were 80.5%, 65.5%, and 55.9%, respectively. The ID was not significantly associated with initial pain relief, or affect the risk of pain recurrence or sensory dysfunction after SRS using the Cox proportional hazards model. A nerve mean dose ≥65 Gy was associated with a reduced risk of pain recurrence on multivariate analysis (hazard ratio 0.408, P = .039). Twenty (21%) patients experienced sensory dysfunction after SRS with 3 (3%) requiring further medications, which was not correlated with the prescription dose or brainstem maximum dose. CONCLUSION/CONCLUSIONS:The ID did not predict recurrence-free survival or sensory dysfunction. Our observations suggest improved nerve coverage by the most powerful area of the isocenter, for instance, by targeting a narrower segment if feasible, could result in more durable pain relief. Further studies to validate these findings are needed.
PMID: 39194227
ISSN: 1524-4040
CID: 5729752
Point/Counterpoint: The role of reirradiation in recurrent glioblastoma
Rahman, Rifaquat; Preusser, Matthias; Tsien, Christina; Le Rhun, Emilie; Sulman, Erik P; Wen, Patrick Y; Minniti, Giuseppe; Weller, Michael
PMID: 39527460
ISSN: 1523-5866
CID: 5752682
Radioligand therapies in meningioma - evidence and future directions
Mair, Maximilian J; Tabouret, Emeline; Johnson, Derek R; Sulman, Erik P; Wen, Patrick Y; Preusser, Matthias; Albert, Nathalie L
Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grade 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters. Alongside, integrated molecular imaging allows for a non-invasive assessment of predictive biomarkers as treatment targets. Whereas the concept of "theranostics" has initially evolved in extracranial tumors such as thyroid diseases, neuroendocrine tumors, and prostate cancer, data from retrospective case series and early phase trials underscore the potential of this strategy in meningioma. This review aims to explore the available evidence of radionuclide treatments and ongoing clinical trial initiatives in meningioma. Moreover, we discuss optimal clinical trial design and future perspectives in the field, including compound- and host-specific determinants of the efficacy of "theranostic" treatment approaches.
PMID: 38702966
ISSN: 1523-5866
CID: 5734342
Targeted radionuclide therapy for gliomas: emerging clinical trial landscape
Weller, Michael; Albert, Nathalie L; Galldiks, Norbert; Bink, Andrea; Preusser, Matthias; Sulman, Erik P; Treyer, Valerie; Wen, Patrick Y; Tonn, Joerg C; Le Rhun, Emilie
According to the new WHO classification of 2021, gliomas are a heterogeneous group of tumors with very different histology, molecular genetics and prognoses. In addition to glioblastomas, the most common gliomas, there are also numerous less common gliomas, some of which have a very favorable prognosis. Targeted radionuclide therapy is a therapeutic option that can be attractive if a tumor can be targeted based on its molecular characteristics. It is particularly useful when tumors cannot be completely resected or when conventional imaging does not fully capture the extent of the tumor. Numerous approaches to radionuclide therapy for gliomas are in early development. The most advanced approaches for patients with gliomas in the clinic employ L-type amino acid transporter 1 as an uptake mechanism for radiolabeled amino acids or target somatostatin receptor 2 or gastrin-releasing peptide receptor. Here, we discuss the various target structures of radionuclide therapy in gliomas and provide an outlook for which glioma entities radionuclide therapy could most likely provide a therapeutic alternative.
PMID: 39107236
ISSN: 1523-5866
CID: 5730642
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial
Sarkaria, Jann N; Ballman, Karla V; Kizilbash, Sani H; Sulman, Erik P; Giannini, Caterina; Friday, Bret B; Butowski, Nicholas A; Mohile, Nimish A; Piccioni, David E; Battiste, James D; Drappatz, Jan; Campian, Jian L; Mashru, Sandeep; Jaeckle, Kurt A; O'Brien, Barbara J; Dixon, Jesse G; Kabat, Brian F; Laack, Nadia L; Hu, Leland S; Kaufmann, Timothy; Kumthekar, Priya; Ellingson, Benjamin M; Anderson, S Keith; Galanis, Evanthia
IMPORTANCE/UNASSIGNED:The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields. OBJECTIVES/UNASSIGNED:To evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib when combined with temozolomide. DESIGN, SETTING, AND PARTICIPANTS/UNASSIGNED:Patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation who had completed concomitant radiation and temozolomide were enrolled between December 15, 2014, and December 15, 2018, in this Alliance for Clinical Trials in Oncology trial. The data for this analysis were locked on April 21, 2023. INTERVENTIONS/UNASSIGNED:Patients were randomized and treated with standard adjuvant temozolomide (150-200 mg/m2 orally, days 1-5) combined with either placebo or veliparib (40 mg orally, twice daily, days 1-7) for 6 cycles. MAIN OUTCOMES AND MEASURES/UNASSIGNED:The primary end point for the phase 3 portion of the trial was overall survival (OS). RESULTS/UNASSIGNED:There were 322 patients randomized during the phase 2 accrual period and an additional 125 patients randomized to complete the phase 3 accrual, for a total of 447 patients in the final phase 3 analysis. The median (range) age for patients was 60 (20-85) years and 190 patients (42.5%) were female. The median OS was 24.8 months (90% CI, 22.6-27.7) for the placebo arm and 28.1 months (90% CI, 24.3-33.3) for the veliparib arm (P = .17). The difference in survival did not meet the prespecified efficacy end point. However, there was a separation of the survival curves that favored the veliparib arm over 24 to 48 months of follow-up. The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects. CONCLUSIONS AND RELEVANCE/UNASSIGNED:This trial found that adding veliparib to adjuvant temozolomide did not significantly extend OS in patients with newly diagnosed, MGMT-hypermethylated glioblastoma. TRIAL REGISTRATION/UNASSIGNED:ClinicalTrials.gov Identifier: NCT02152982.
PMCID:11528341
PMID: 39480453
ISSN: 2374-2445
CID: 5747282
Outcomes of Radiosurgery for WHO Grade 2 Meningiomas: The Role of Ki-67 Index in Guiding the Tumor Margin Dose
Meng, Ying; Bernstein, Kenneth; Mashiach, Elad; Santhumayor, Brandon; Kannapadi, Nivedha; Gurewitz, Jason; Snuderl, Matija; Pacione, Donato; Sen, Chandra; Donahue, Bernadine; Silverman, Joshua S; Sulman, Erik; Golfinos, John; Kondziolka, Douglas
BACKGROUND AND OBJECTIVES/OBJECTIVE:The management of World Health Organization (WHO) grade 2 meningiomas is complicated by their diverse clinical behaviors. Stereotactic radiosurgery (SRS) can be an effective management option. Literature on SRS dose selection is limited but suggests that a higher dose is better for tumor control. We characterize the predictors of post-SRS outcomes that can help guide planning and management. METHODS:We reviewed a cohort of consecutive patients with pathologically-proven WHO grade 2 meningiomas who underwent SRS at a single institution between 2011 and 2023. RESULTS:Ninety-nine patients (median age 62 years) underwent SRS, 11 of whom received hypofractionated SRS in 5 fractions. Twenty-two patients had received previous irradiation. The median follow-up was 49 months. The median overall survival was 119 months (95% CI 92-NA) with estimated 5- and 10-year survival of 83% and 27%, respectively. The median progression-free survival (PFS) was 40 months (95% CI 32-62), with 3- and 5-year rates at 54% and 35%, respectively. The median locomarginal PFS was 63 months (95% CI 51.8-NA) with 3- and 5-year rates at 65% and 52%. Nine (9%) patients experienced adverse events, 2 Common Terminology Criteria for Adverse Events grade 3 and 7 grade 2, consisting of worsening neurologic deficit from edema. In the single-session cohort, Ki-67 significantly predicted both overall survival and intracranial PFS. Tumors with Ki-67 >10% had 2.17 times the risk of locomarginal progression compared with Ki-67 ≤10% (P = .018) adjusting for covariates. Sex, prescription dose, tumor volume, and location also predicted tumor control. In tumors with Ki-67 >10%, margin dose ≥14 Gy was associated with significantly better tumor control but not for tumors with Ki-67 ≤10%. CONCLUSION/CONCLUSIONS:The management of WHO grade 2 meningiomas requires a multimodality approach. This study demonstrates the value of a targeted SRS approach in patients with limited disease and further establishes predictive biomarkers that can guide planning through a personalized approach.
PMID: 39526756
ISSN: 1524-4040
CID: 5752612
Meningioma: International Consortium on Meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients
Wang, Justin Z; Landry, Alexander P; Raleigh, David R; Sahm, Felix; Walsh, Kyle M; Goldbrunner, Roland; Yefet, Leeor S; Tonn, Jörg C; Gui, Chloe; Ostrom, Quinn T; Barnholtz-Sloan, Jill; Perry, Arie; Ellenbogen, Yosef; Hanemann, C Oliver; Jungwirth, Gerhard; Jenkinson, Michael D; Tabatabai, Ghazaleh; Mathiesen, Tiit I; McDermott, Michael W; Tatagiba, Marcos; la Fougère, Christian; Maas, Sybren L N; Galldiks, Norbert; Albert, Nathalie L; Brastianos, Priscilla K; Ehret, Felix; Minniti, Giuseppe; Lamszus, Katrin; Ricklefs, Franz L; Schittenhelm, Jens; Drummond, Katharine J; Dunn, Ian F; Pathmanaban, Omar N; Cohen-Gadol, Aaron A; Sulman, Erik P; Tabouret, Emeline; Le Rhun, Emelie; Mawrin, Christian; Moliterno, Jennifer; Weller, Michael; Bi, Wenya Linda; Gao, Andrew; Yip, Stephen; Niyazi, Maximilian; ,; Aldape, Kenneth; Wen, Patrick Y; Short, Susan; Preusser, Matthias; Nassiri, Farshad; Zadeh, Gelareh
Meningiomas are the most common primary intracranial tumors in adults and are increasing in incidence due to the aging population and increased access to neuroimaging. While most exhibit nonmalignant behavior, a subset of meningiomas are biologically aggressive and are associated with treatment resistance, resulting in significant neurologic morbidity and even mortality. In recent years, meaningful advances in our understanding of the biology of these tumors have led to the incorporation of molecular biomarkers into their grading and prognostication. However, unlike other central nervous system (CNS) tumors, a unified molecular taxonomy for meningiomas has not yet been established and remains an overarching goal of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official World Health Organization (cIMPACT-NOW) working group. Additionally, clinical equipoise still remains on how specific meningioma cases and patient populations should be optimally managed. To address these existing gaps, members of the International Consortium on Meningiomas including field-leading experts, have prepared this comprehensive consensus narrative review directed toward clinicians, researchers, and patients. Included in this manuscript are detailed overviews of proposed molecular classifications, novel biomarkers, contemporary treatment strategies, trials on systemic therapies, health-related quality-of-life studies, and management strategies for unique meningioma patient populations. In each section, we discuss the current state of knowledge as well as ongoing clinical and research challenges to road map future directions for further investigation.
PMCID:11449035
PMID: 38695575
ISSN: 1523-5866
CID: 5706662